FCF YoY
-78.11%
OCF YoY
-78.83%
Capex YoY
+37.04%
FCF Conversion Δ
—
Free cash flow bridge for Revolution Medicines (RVMD) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Free cash flow: −$470.01M
FCF bridge breakdown for Revolution Medicines (RVMD) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Free Cash Flow | −$601.72M | — |
| Operating Cash Flow | −$466.16M | -99.2% |
| Capital Expenditure | −$3.85M | -0.8% |
| Free Cash Outflow | −$1.07B | — |
- Prior Free Cash Flow−$601.72M
- Operating Cash Flow−$466.16M
- Capital Expenditure−$3.85M
- Free Cash Outflow−$1.07B
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want to see how cash flow is built up?Cash Flow Waterfall
Frequently asked questions
Data & methodology
Revolution Medicines (RVMD) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement